Active Pharmaceutical Ingredient (API) Market, by Product Type (Low Potent APIs and High Potent APIs), by Molecular Type (Small Molecules and Large Molecules), by Formulation (Oral, Topical, Injectables, and Drops), by Application (Diabetes, Oncology, Car

Active Pharmaceutical Ingredient (API) Market, by Product Type (Low Potent APIs and High Potent APIs), by Molecular Type (Small Molecules and Large Molecules), by Formulation (Oral, Topical, Injectables, and Drops), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, Ophthalmic, Respiratory, Dermatology, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Active pharmaceutical ingredients (APIs) and excipients are the two most important components in the production of a medication. API is the raw material, which is used in manufacturing medications, whereas excipient is a substance that functions as a medium to help the body absorb the drug such as lactose or mineral oil in a tablet. Active pharmaceutical ingredients are produced by using highly technological industrial processes, both during the research & development and commercial production phases. Such compounds are developed to provide pharmacological activity or other direct impacts on disease diagnosis, cure, mitigation, therapy, or prevention, or to change the structure and function of the body. The growth of active pharmaceutical ingredient (API) market can be attributed to certain factors such as increasing funding initiatives by the government across different regions. For instance, in May 2021, the U.S. Department of Health and Human Services (HHS) announced that it will provide a funding of US$ 354 million to Phlow Corporation, a pharmaceutical company, under a four-year contract to produce the active pharmaceutical ingredients (APIs) needed for medications to treat patients with COVID-19 and related illnesses.
Market Dynamics
The rising U.S Food & Drug Administration (FDA) approvals for drugs by pharmaceutical companies is further expected to boost the global active pharmaceutical ingredient (API) market growth during the forecast period. For instance, in December 2021, Eily Lilly received the U.S FDA clearance for several medicines including increased dosages of its Trulicity therapy for the treatment of type 2 diabetes, Cyramza for the treatment of metastatic Estimated Glomerular Filteration Rate (EGFR)-mutated non-small cell lung cancer, and tauvid for individuals diagnosed with Alzheimer's disease.
Key features of the study:
This report provides an in-depth analysis of the global active pharmaceutical ingredient (API) market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global active pharmaceutical ingredient (API) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG, and Biological E. Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global active pharmaceutical ingredient (API) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global active pharmaceutical ingredient (API) market
Detailed Segmentation:
Global Active Pharmaceutical Ingredient (API) Market, By Product Type:
Low Potent APIs
High Potent APIs
Global Active Pharmaceutical Ingredient (API) Market, By Molecular Type:
Small Molecules
Large Molecules
Global Active Pharmaceutical Ingredient (API) Market, By Formulation:
Oral
Topical
Injectable
Drops
Global Active Pharmaceutical Ingredient (API) Market, By Application:
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
Global Active Pharmaceutical Ingredient (API) Market, By Region:
North America
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country
U.S.
Canada
Latin America
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Low Potent APIs
High Potent APIs
By Molecular Type
Small Molecules
Large Molecules
By Formulation
Oral
Topical
Injectables
Drops
By Application
Diabetes
Oncology
Cardiovascular
CNS
Analgesics
Ophthalmic
Respiratory
Dermatology
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer, Inc.
Reddy’s Laboratories Ltd.
Novartis AG
Mylan N.V.
Amneal Pharmaceuticals LLC
Lonza Group
Lupin Limited
Fresenius Kabi
Hikma Pharmaceuticals
Cipla Limited
Glenmark Pharmaceuticals Limited
Sun Pharmaceutical Industries Ltd.
Endo International plc
Aurobindo Pharma Limited
Apotex Inc.
Taro Pharmaceutical Industries Ltd
Stada Arzneimittel AG
Krka Pharmaceuticals
CordenPharma International
Evonik Industries AG
Biological E. Limited
“*” marked represents similar segmentation in other categories in the respective section.